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May Supplement 200948S Rapid Paced Paper SessionsMethods: 178 consecutive EVARs had concurrent CardioMEMS En-
doSure® implantation during Jan. 2007-Dec. 2008. Post-operative intrasac
pressure was measured at every office visit. Ratios of sac to systemic pressures
were recorded as mean (MPI) and pulse (PPI) pressure indexes. CT scans
were obtained at every 6 months or anytime an endoleak was suspected.
Aneurysm sac volume was quantitated after constructed by volume render-
ing of CTA.
Results: Technical success of EndoSure implantation was 98%
(175/178). No sensor malfunctioned after successful implantation.
Mean follow-up was 12.5 months (range 1 - 24 months). In EVAR
without endoleak (143/175), sac pressure decreased progressively and
remained plateaued (MPI  0.5, PPI  0.5) for 24 months. There was a
strong correlation (r  0.87) between diminishing sac pressure and
shrinking sac size. Thirty-two endoleaks developed (18.5%). Five type I
endoleaks (3%) were discovered by sac pressure elevation (MPI  0.5)
and pulsatile waveform (PPI  0.5) (Positive Predictive Value 100%).
Twenty-seven type II endoleaks or endotensions (15.5%) were suspected
with variant MPI elevation ( 0.5) but normal PPI ( 0.5)(PPV 100%).
Endoleaks with markedly elevated sac pressure (MPI  1.0) were fol-
lowed by sac volume expansion.
Conclusions: EVAR can be surveillanced safely by sac pressure
monitoring up to 2 years. The type of endoleak can be predicted based on
the character of sac pressure elevation. Suspected endoleak should be
further examined by CTA with sac volume quantitation. Consistent sac
pressure elevation with sac volume expansion warrants aggressive
intervention.
Summary of sac pressure and volume change during
EVAR surveillance
N  175 MPI PPI Sac volume
No endoleak 143  0.5  0.5 Decrease
Type I endoleak 5  0.5  0.5 Same or
increase
Type II endoleak 25  0.5  0.5 Increase if MPI
 1.0
Endotension 2  0.5  0.5 Increase if MPI
 1.0
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Background: The mortality of ruptured abdominal aortic aneurysm
(rAAA) repair is currently 40-50%. Reports indicate that endovascular repair
(EVAR) is feasible for rAAA and may offer potential benefits over open
repair. We examined the NSQIP database to compare 30-day multicentre
outcomes for EVAR vs. open rAAA repair.
Methods: Patients that underwent rAAA repair in the NSQIP database
from 2005 to 2007 were identified through a combination of CPT codes
and ICD-9 diagnoses. Preoperative comorbidities, operative duration and
transfusion, and 30 day outcomes were evaluated using T-tests.
Results: 76.8% of patients underwent open repair as shown:
EVAR Open repair
All
rAAA
Year n % n % n
2005 4 9.3 39 90.7 43
2006 32 24.2 100 75.8 132
2007 63 25.0 189 75.0 252
Total 99 23.2 326 76.8 427EVAR Open repair P
Patient
Characteristics
Age mean years 
S.D.
72.110.5 73.69.3 0.167
Male % 79.8 76.5 0.497
Smoking % 39.4 30.8 0.111
COPD % 19.2 13.4 0.156
Hx. of Angina, MI
or CHF %
9.1 5.8 0.246
Prior Cardiac
Operation or
PCI %
27.3 21.3 0.218
Treated
Hypertension %
64.6 66.8 0.696
Preop. Transfusion
4 u PRBCs %
2.0 6.1 0.108
Preop Albumin
mean g/dL 
S.D.
3.560.78 3.300.73 0.017*
Intraoperative
Variables
Operative time
mean min. 
S.D.
195.0113.4 203.389.5 0.449
Units PRBC
Intraop. mean 
S.D.
4.26.0 11.88.9 0.001*
Postoperative
Outcomes
30 day composite
morbidity (%)
45.5 62.5 0.003*
30 day mortality
(%)
22.2 37.2 0.003*
Wound dehiscence
(%)
0 4.6 0.030*
Ventilator  48
hours (%)
23.2 47.6 0.001*
Sepsis/septic
shock (%)
19.2 29.9 0.037*
Pulmonary adverse
events (%)
34.3 50.0 0.006*
Patient characteristics, intraoperative variables and postoperative outcomes
are summarized in the table above. Groups were comparable in terms of
comorbid conditions, age and gender; requirement for preoperative blood
transfusion indicative of hemodynamic status was similar. Open repair
resulted in much higher requirement for blood transfusion(P0.001) with-
out difference in operating time. Mortality was higher after OR (
P0.003).There was no difference in the rate of cardiac, neurologic or renal
complications but composite morbidity was higher after open repair second-
ary to wound, septic and pulmonary complications.
Conclusions: EVAR appears to offer superior 30 day outcomes after
repair of rAAA. We did not access aneurysm anatomic characteristics to deter-
mine how many patients that had open repair would have been candidates for
EVAR.Theanatomic suitability forEVARhasbeen reported at60% for rAAA.Less
that ¼ of the NSQIP database patients underwent EVAR; preoperative albumin
which is a strong predictor of morbidity and mortality was significantly lower in
patients undergoingopen repair. There has beenno increase in the ratio ofEVAR/
open repair in the last two years. EVAR for rAAA with favorable anatomy could
potentially result in lower mortality andmorbidity as compared to open repair.
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